Drugs / ThisCART19 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05106907 | Oct 2021 → Oct 2023 | B-cell neoplasm | Fundamenta Therapeutics, Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ThisCART19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05106907 ↗ |
| Modality | Cell therapy | “ThisCART19 cell is a non-gene-editing allogeneic CAR-T cell targeting CD19.” NCT05106907 ↗ |
| Target | CD19 | “ThisCART19 cell is a non-gene-editing allogeneic CAR-T cell targeting CD19.” NCT05106907 ↗ |